Fennec Pharmaceuticals Expands PEDMARK Study to Adult and AYA Cancer Patients
Event summary
- University of Arizona Cancer Center initiates Phase I/II study of PEDMARK® in AYA and adult patients with head and neck and testicular cancers.
- Fennec Pharmaceuticals has three ongoing investigator-sponsored studies exploring PEDMARK® in new patient populations.
- PEDMARK® is currently FDA-approved for pediatric patients but seeks label expansion for adult and AYA populations.
- Study aims to evaluate PEDMARK®'s efficacy in reducing cisplatin-induced ototoxicity in adult patients.
The big picture
Fennec Pharmaceuticals is strategically expanding the clinical validation of PEDMARK® beyond its current pediatric approval, targeting a larger patient population affected by cisplatin-induced ototoxicity. The initiation of multiple investigator-sponsored studies signals a push for real-world evidence to support label expansion, aligning with broader industry trends toward personalized and preventive oncology treatments. The company's partnership with Norgine Pharmaceuticals further strengthens its global commercialization strategy.
What we're watching
- Regulatory Pathways
- Whether Fennec can secure FDA label expansion for PEDMARK® in adult and AYA populations based on investigator-sponsored study results.
- Clinical Adoption
- The pace at which real-world evidence from these studies drives broader clinical adoption of PEDMARK®.
- Market Expansion
- How successful PEDMARK®'s commercialization will be in new geographic markets through Norgine Pharmaceuticals' licensing agreement.
Related topics